However, approximately primary resistance invariably emerged in 20% of CML patients to imatinib and 30% of EGFR-mutated NSCLC patients to EGFR-TKI therapy4, 5, 6, revealing that personalized difference in genetic background might influence treatment efficacy of TKI in cancer patients. This evidence concerns the gene EGFR and chronic myelogenous leukemia, BCR-ABL1 positive.